BO-112 With Pembrolizumab in Unresectable Malignant Melanoma (SPOTLIGHT203)
Phase 2 Single Arm Clinical Study to Evaluate the Efficacy and Safety of Intratumoral Administration of BO-112 in Combination With Pembrolizumab in Subjects That Have Progressed on Anti-PD-1-based Therapy for Stage III or IV Melanoma
Sponsor: Highlight Therapeutics
This PHASE2 trial investigates Melanoma and is currently completed. Highlight Therapeutics leads this study, which shows 12 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 7 earlier versions
-
Jan 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE2
-
Mar 2022 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Mar 2021 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2020 — Nov 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Highlight Therapeutics
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Badalona, Spain , Barcelona, Spain , Bordeaux, France , Grenoble, France , Lyon, France , Madrid, Spain , Murcia, Spain , Nantes, France , Nice, France , Pamplona, Spain and 4 more locations